Data integrity focus of FDA warning letter
This article was originally published in The Gold Sheet
Executive Summary
An Oct. 23 warning letter cited Sanofi-Aventis for failing to take action against a clinical investigator who had falsified case report forms and documentation to support the existence of a fictitious subject. FDA alleges that Aventis failed to secure compliance of the investigator, terminate the investigator or stop shipping the drug, Ketek, an antibiotic, and notify the agency after discovering violations, as required by FDA. The letter is another signal that FDA investigators are continuing to focus attention on data integrity issues
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.